NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9200
+0.0200 (+1.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.9000
Open1.9200
Bid1.90 x 3200
Ask1.92 x 2900
Day's Range1.8700 - 1.9350
52 Week Range1.1500 - 2.7500
Volume6,905,056
Avg. Volume9,215,880
Market Cap735.072M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.38
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Research Report Identifies Novavax, Zillow Group, Broadridge Financial Solutions, Summit Midstream Partners, LP, Primoris Services, and RE/MAX with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
    Zacks11 days ago

    Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

    Novavax (NVAX) closed the most recent trading day at $2.19, moving -0.45% from the previous trading session.

  • Novavax (NVAX) Gains As Market Dips: What You Should Know
    Zacks17 days ago

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $2.30, marking a +0.44% move from the previous day.

  • Analyst: This Medical Stock Could Triple
    Schaeffer's Investment Research26 days ago

    Analyst: This Medical Stock Could Triple

    H.C. Wainwright has high hopes for the company's vaccine

  • ACCESSWIRE27 days ago

    4 Healthcare Stocks Looking For A Healthy Start On Monday (1/28/19)

    With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Why Short-Sellers Raised Their Bets Against 2 Surging Biotech Stocks
    Motley Fool27 days ago

    Why Short-Sellers Raised Their Bets Against 2 Surging Biotech Stocks

    Find out why some aren't nearly as enthusiastic about the future for these two biotech stocks.

  • ACCESSWIRElast month

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • 3 High-Growth Stocks That Could Soar
    Motley Foollast month

    3 High-Growth Stocks That Could Soar

    Novavax, A.O. Smith, and XPO Logistics could be three stocks that are only just getting started.

  • ACCESSWIRElast month

    Best Bottom Bouncing Opportunities

    HENDERSON, NV / ACCESSWIRE / January 17, 2019 / Below are some incredible opportunities in the market today. Gopher Protocol Inc. (GOPH) , is an absolutely fascinating company that was trading has a 52-week ...

  • Here's How Novavax Stock Gained 48.4% in 2018
    Motley Foollast month

    Here's How Novavax Stock Gained 48.4% in 2018

    Progress with two vaccines pushed the stock up last year.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...

  • 3 Great Stocks Under $10
    Motley Foollast month

    3 Great Stocks Under $10

    It's not the low share price that makes these stocks attractive, it's their huge growth prospects.

  • Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
    Zackslast month

    Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

    Is (NVAX) Outperforming Other Medical Stocks This Year?

  • Top 3 Healthcare Penny Stocks for 2018
    Investopedia2 months ago

    Top 3 Healthcare Penny Stocks for 2018

    These three healthcare penny stocks are poised for positive performance in the final quarter of 2018.

  • Novavax Rose Due to Positive NanoFlu Vaccine Results
    Market Realist2 months ago

    Novavax Rose Due to Positive NanoFlu Vaccine Results

    Novavax Rose Due to Positive NanoFlu Vaccine Results ## Share price movements On January 3, Novavax (NVAX) issued a press release announcing positive top-line results from the Phase 2 trial comparing the safety and immunogenicity of its multiple NanoFlu vaccine formulations. Two influenza vaccines are already licensed in the United States for healthy, older adults. According to the press release, the company plans to schedule an end-of-Phase 2 meeting with the FDA and start the pivotal Phase 3 trial for the vaccine in 2019. Novavax expects the FDA to allow the company to pursue an accelerated approval pathway for NanoFlu, which would allow it to secure a US license in the coming years. After the announcement, Novavax reported a 3.55% rise in the share prices from $1.97 on January 2 to $2.04 on January 3. The company closed at $2.14 on January 4, which is 4.90% higher compared to the previous closing price. Based on its closing price on January 4, the company reported returns of 13.83% in the last week, -2.28% in the last month, and 2.39% in the last quarter. Novavax also reported returns of 56.20% in the second half of 2018, 58.52% in 2018, and 16.30% YTD. ## Analysts’ recommendations and target price On January 7, analysts’ consensus 12-month recommendation for Novavax is a “buy.” The 12-month consensus target price for the company is $4.5, which is 110.28% higher than its closing price on January 4. The highest target price estimate for the company is $10, while the lowest target price estimate is $1.5. Among the eight analysts covering Novavax on January 7, three recommended a “strong buy,” three recommended a “buy,” and two recommended a “hold.”

  • Why GameStop, Novavax, and Epizyme Jumped Today
    Motley Fool2 months ago

    Why GameStop, Novavax, and Epizyme Jumped Today

    It was a great day for the overall market. Find out why these stocks stood out.

  • Novavax kicks off 2019 with positive flu vaccine trial results
    American City Business Journals2 months ago

    Novavax kicks off 2019 with positive flu vaccine trial results

    Novavax Inc. is starting 2019 on a high note, reporting positive phase 2 results for its flu vaccine candidate Thursday in what is expected to be a critical year for the Gaithersburg biotech. The clinical trial for NanoFlu, which compared elderly adults’ immune responses to two flu vaccines on the market, found that its formulations were well-tolerated — and 50 percent more effective than market leader Fluzone High-Dose. The results sent Novavax (NASDAQ: NVAX) shares up more than 6 percent Thursday and Friday.

  • ACCESSWIRE2 months ago

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • Why Novavax's Stock Is Surging Today
    Motley Fool2 months ago

    Why Novavax's Stock Is Surging Today

    Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.

  • ACCESSWIRE2 months ago

    Biotech Stocks Set to Start 2019 Off with a Bang

    HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...

  • MarketWatch2 months ago

    Novavax shares jump after positive results for flu vaccine

    Novavax Inc. shares soared up to 12% higher in after-hours trading Thursday, when the company announced positive results for its NanoFlu flu vaccine candidate. "These confirmatory data from the second clinical trial of NanoFlu further justify continued rapid development of an improved vaccine," Novavax executive Gregory Glenn said in Thursday's news release. Novavax disclosed that it will meet with the Food and Drug Administration in the first half of this year to discuss the results and plan for a Phase 3 trial of the vaccine, which the company said it expects to launch this year. The NanoFlu vaccine has shown strong results in the past against the H3N2 flu strain, which has been a problem for standard vaccines; the Phase 2 study focused on usage in older adults. After closing with a 3.6% gain at $2.04, shares neared $2.30 in late trading after the announcement.

  • GlobeNewswire2 months ago

    Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults

    The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax’ Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older.

  • GlobeNewswire2 months ago

    Novavax to Present at the 37th Annual J.P. Morgan Healthcare Conference

    GAITHERSBURG, Md., Jan. 02, 2019 -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference. Presentation details.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Gaining Speed on Wednesday (1/2/19)

    CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / As we dive, head-first into the new year, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NASDAQ: NVAX), Rite Aid Corporation (NYSE:RAD), and Bausch Health Companies Inc (NYSE: BHC) are 4 healthcare stocks representing companies prepared to innovate towards the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company dominating the telehealth sector of the healthcare industry, enjoyed a strong month of bullish trading back in December, with Company shares soaring well above the 30% mark in a 30-day period.